{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:07:00Z","timestamp":1790838420887,"version":"4.1.0"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the efficacy and safety of dapagliflozin therapy in children with heart failure with reduced ejection fraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This was a retrospective cohort study based on electronic medical records. For the retrospective cohort study, 32 children with heart failure with reduced ejection fraction diagnosed at Shanghai Children's Medical Center and Fujian Children's Hospital from June 2021 to June 2023 and who were treated with dapagliflozin were enrolled. For pediatric patients weighing &amp;lt;10\u2005kg, dapagliflozin was administered at a dosage of 0.2\u2005mg\/kg\/d. Patients with a body weight ranging from 10\u2005kg to less than 20\u2005kg (20\u2009&amp;gt;\u2009weight \u226510\u2005kg) received dapagliflozin at a dose of 2.5\u2005mg\/d. Those weighing between 20\u2005kg and less than 30\u2005kg (30\u2009&amp;gt;\u2009weight \u226520\u2005kg) were prescribed dapagliflozin at 5\u2005mg\/d. For patients weighing 30\u2005kg or more, the initial dose of dapagliflozin was 5\u2005mg\/d, which was increased to 10\u2005mg\/d after one month. 42 children treated during the same period without dapagliflozin were included as the control group. All children were treated with standard guideline-directed triple combination of ACEI\/ARNI,\n                      <jats:italic>\u03b2<\/jats:italic>\n                      -blocker, and aldosterone receptor antagonist. Clinical characteristics, underlying diseases, cardiac function ratings, left ventricular ejection fraction, B-type natriuretic peptide, and blood biochemical indexes were collected. Changes in cardiac function ratings, left ventricular ejection fraction, and B-type natriuretic peptide at 24 (\u00b12) weeks of treatment were observed; the incidence of hospitalization or death due to exacerbation of heart failure at 24 (\u00b12) weeks of treatment was observed secondarily. Adverse medicine events such as hypoglycemia or hypotension were also observed during treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 32 children, 20 were male and 12 were female, aged (6.32\u2009\u00b1\u20094.00) years; weight (22.19\u2009\u00b1\u200912.66)\u2005kg. The underlying diseases included dilated cardiomyopathy in 25 cases, dilated cardiomyopathy combined with complete left bundle branch block in two cases, postoperative congenital heart disease in four cases, and atrial tachycardia in one case. At 24 (\u00b12) weeks of treatment, left ventricular ejection fraction level significantly increased compared with baseline (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001); B-type natriuretic peptide decreased (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001); and New York Heart Association (NYHA) cardiac function ratings improved significantly (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.034). Compared with the control group, children in the dapagliflozin group showed greater improvement in left ventricular ejection fraction (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.032) and NYHA cardiac function rating (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.038), whereas no significant difference was observed in BNP levels (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.071). Three children developed urinary tract infection during the administration of the medication, and three children developed hypotension, while no other adverse reactions, such as hypoglycemia or hepatic or renal function impairment, were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dapagliflozin was associated with improvements in left ventricular ejection fraction, BNP, and NYHA cardiac function classification in children with heart failure with reduced ejection fraction. No hospitalization or death due to the deterioration of heart failure and no serious adverse reactions were observed. The treatment was generally well tolerated, and the weight-stratified dosing strategy showed acceptable short-term safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1785458","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:20:36Z","timestamp":1776403236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effect of dapagliflozin on heart failure with reduced ejection fraction in children"],"prefix":"10.3389","volume":"13","author":[{"given":"Shaoyong","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Children\u2019s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Children\u2019s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Children\u2019s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Children\u2019s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai Children\u2019s Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fujian Children\u2019s Hospital (Fujian Branch of Shanghai Children\u2019s Medical Center), College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 Inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamacardio.2022.3736","article-title":"Effect of dapagliflozin on cause-specific mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER","volume":"7","author":"Desai","year":"2022","journal-title":"JAMA Cardiology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s12098-022-04433-4","article-title":"Diagnosis and management of pediatric heart failure","volume":"90","author":"Mille","year":"2023","journal-title":"Indian J Pediatr"},{"key":"B8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.pcl.2020.06.004","article-title":"Update of pediatric heart failure","volume":"67","author":"Watanabe","year":"2020","journal-title":"Pediatr Clin N Am"},{"key":"B9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1542\/pir.2016-0168","article-title":"Congestive heart failure in children","volume":"40","author":"Price","year":"2019","journal-title":"Pediatrics in Review"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1007\/s00125-023-05975-8","article-title":"SGLT2i And GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study","volume":"66","author":"Anson","year":"2023","journal-title":"Diabetologia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s13300-021-01004-2","article-title":"Sodium-glucose co-transporter 2 inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies","volume":"12","author":"Caparrotta","year":"2021","journal-title":"Diabetes Ther"},{"key":"B12","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","article-title":"Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes","volume":"45","author":"Wright","year":"2022","journal-title":"Diabetes Care"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"B14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1007\/s00246-022-02983-0","article-title":"Early clinical experience with dapagliflozin in children with heart failure","volume":"44","author":"Newland","year":"2023","journal-title":"Pediatr Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3760\/cma.j.cn112140-20220711-00637","article-title":"Short-term efficacy of dapagliflozin in children with hereditary proteinuric kidney disease","volume":"61","author":"Cui","year":"2023","journal-title":"Chin J Pediatr"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1785458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:20:38Z","timestamp":1776403238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1785458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":15,"alternative-id":["10.3389\/fcvm.2026.1785458"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1785458","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1785458"}}